Prostate-specific antigen-based screening for prostate cancer in the third millennium: Useful or hype?

References

• Lim, LS, Sherin, K; ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008;34:164–70.
   PubMed Web of Science ®Google Scholar
• Sutcliffe, P, Hummel, S, Simpson, E, Young, T, Rees, A, Wilkinson, A, , et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess. 2009;13:,iii: xi–xiii, 1–219.
   Google Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2004; 16: 481–8
   Web of Science ®Google Scholar
• Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009; 53: 171–84
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225–49
   PubMed Web of Science ®Google Scholar
• Gann PH. Risk factors for prostate cancer. Rev Urol 2002; 4(Suppl 5)S3–10
   PubMedGoogle Scholar
• Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007; 177: 444–9
   PubMed Web of Science ®Google Scholar
• Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vilá H, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2825–34
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology?. Prostate. 2005; 62: 243–52
   PubMed Web of Science ®Google Scholar
• Damber JE, Aus G. Prostate cancer. Lancet. 2008; 371: 1710–21
   PubMed Web of Science ®Google Scholar
• Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993; 118: 793–803
   PubMed Web of Science ®Google Scholar
• Edwards CN, Steinthosson E, Nicholson D. An autopsy study of latent prostatic cancer. Cancer. 1953; 6: 531–54
   PubMed Web of Science ®Google Scholar
• Halpert B, Sheehan E, Schmalhorst W, Scott R. Carcinoma of the prostate: A survey of 5000 autopsies. Cancer. 1963; 16: 737–42
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Parker AS, Putnam SD, Chiu BCH, Lynch CF, Cohen MB, et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev. 1999; 8: 53–60
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343: 78–85
   PubMed Web of Science ®Google Scholar
• Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate. 1997; 33: 240–5
   PubMed Web of Science ®Google Scholar
• Gibbs M, Stanford JL, Jarvik GP, Janer M, Badzioch M, Peters MA, et al. A genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Hum Genet. 2000; 67: 100–9
   PubMed Web of Science ®Google Scholar
• Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet. 1998; 62: 1416–24
   PubMed Web of Science ®Google Scholar
• Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, et al. Evidence for a rare prostate cancer susceptibility locus at chromosome 1p36. Am J Hum Genet. 1999; 64: 776–87
   PubMed Web of Science ®Google Scholar
• Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998; 20: 175–9
   PubMed Web of Science ®Google Scholar
• Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet. 2000; 67: 82–91
   PubMed Web of Science ®Google Scholar
• Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, et al. Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate. 2003; 57: 326–34
   PubMed Web of Science ®Google Scholar
• Stanford JL, Fitzgerald LM, McDonnell SK, Carlson EE, McIntosh LM, Deutsch K, et al. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet. 2009; 18: 1839–48
   PubMed Web of Science ®Google Scholar
• Hsing AW. Hormones and prostate cancer: Where do we go from here?. J Natl Cancer Inst. 1996; 88: 1093–5
   PubMedGoogle Scholar
• Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000; 10: 361–9
   PubMed Web of Science ®Google Scholar
• Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008; 101: 5–10
   PubMed Web of Science ®Google Scholar
• Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979; 17: 159–63
   PubMedGoogle Scholar
• Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980; 40: 2428–32
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909–16
   PubMed Web of Science ®Google Scholar
• Bélanger A, van Halbeek H, Graves HC, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate. 1995; 27: 187–97
   PubMed Web of Science ®Google Scholar
• Lundwall A, Lilja H. Molecular cloning of human prostate-specific antigen cDNA. FEBS Lett. 1987; 214: 317–22
   PubMed Web of Science ®Google Scholar
• Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997; 57: 3111–4
   PubMed Web of Science ®Google Scholar
• Schieferstein G. Prostate-specific antigen (PSA) in human seminal plasma. Arch Androl. 1999; 42: 193–7
   PubMed Web of Science ®Google Scholar
• Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991; 37: 1618–25
   PubMed Web of Science ®Google Scholar
• Malm J, Lilja H. Biochemistry of prostate specific antigen, PSA. Scand J Clin Lab Invest Suppl. 1995; 221: 15–22
   PubMedGoogle Scholar
• Liang, SL. Application of prostate-specific antigen in prostate cancer. MLO Med Lab Obs. 2008;40:54, 56–7.
   PubMedGoogle Scholar
• Stenman U, Finne P, Zhang W, Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology. 2000; 56: 893–8
   PubMed Web of Science ®Google Scholar
• Basso D, Fogar P, Piva MG, Navaglia F, Mazza S, Prayer-Galetti T, et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?. Urology. 2000; 55: 710–5
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Prostate-specific antigen: a cancer fighter and a valuable messenger?. Clin Chem. 2000; 46: 896–900
   PubMed Web of Science ®Google Scholar
• Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007; 249: 30–9
   PubMed Web of Science ®Google Scholar
• Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007; 176: 1853–8
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239–46
   PubMed Web of Science ®Google Scholar
• Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67: 316–20
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992; 147: 846–51
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997; 277: 1452–5
   PubMed Web of Science ®Google Scholar
• Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, The Netherlands). BJU Int 2003; 92(Suppl 2)48–54
   PubMedGoogle Scholar
• Schröder, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Ciatto, S, Nelen, V, ; ERSPC Investigators, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98: 529–34
   PubMed Web of Science ®Google Scholar
• Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, et al. External validation of the Prostate Cancer Prevention Trial risk calculator. Urology. 2006; 68: 1152–5
   PubMed Web of Science ®Google Scholar
• Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park) 2000;14:267–72.
   PubMedGoogle Scholar
• Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006; 56: 11–25
   PubMed Web of Science ®Google Scholar
• Kawachi, MH, Bahnson, RR, Barry, M, Carroll, PR, Carter, HB, Catalona, WJ, ; National Comprehensive Cancer Network, et al. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5:714–36.
   PubMedGoogle Scholar
• Kerfoot BP, Holmberg EF, Lawler EV, Krupat E, Conlin PR. Practitioner-level determinants of inappropriate prostate-specific antigen screening. Arch Intern Med. 2007; 167: 1367–72
   PubMedGoogle Scholar
• Lippi G, Montagnana M, Guidi GC. Improving appropriateness of prostate-specific antigen screening. Arch Intern Med. 2007; 167: 2529–30
   PubMedGoogle Scholar
• Panteghini M, Pagani F, Bonora R. Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology. Eur J Clin Chem Clin Biochem. 1992; 30: 135–9
   PubMedGoogle Scholar
• Wiklund F, Zheng SL, Sun J, Adami HO, Lilja H, Hsu FC, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate. 2009; 69: 419–27
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270: 860–4
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995; 154: 1090–5
   PubMed Web of Science ®Google Scholar
• Cooney KA, Strawderman MS, Wojno KJ, Doerr KM, Taylor A, Alcser KH, et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology. 2001; 57: 91–6
   PubMed Web of Science ®Google Scholar
• Tewari A, Horninger W, Badani KK, Hasan M, Coon S, Crawford ED, et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2005; 96: 29–33
   PubMed Web of Science ®Google Scholar
• Lacher, DA, Thompson, TD, Hughes, JP, Saraiya, M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001–04. Adv Data. 2006;1–12.
   PubMedGoogle Scholar
• Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006; 107: 2361–7
   PubMed Web of Science ®Google Scholar
• Fowke JH, Signorello LB, Underwood W 3rd, Ukoli FA, Blot WJ. Obesity and prostate cancer screening among African-American and Caucasian men. Prostate. 2006; 66: 1371–80
   PubMed Web of Science ®Google Scholar
• Rundle A, Richards C, Neugut AI. Body composition, abdominal fat distribution, and prostate-specific antigen test results. Cancer Epidemiol Biomarkers Prev. 2009; 18: 331–6
   PubMed Web of Science ®Google Scholar
• Lippi G, Montagnana M, Guidi GC. Epidemiological association between C-reactive protein and prostate-specific antigen. Cancer. 2009; 115: 1132
   PubMed Web of Science ®Google Scholar
• Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry. Clin Biochem. 1998; 31: 475–81
   PubMed Web of Science ®Google Scholar
• Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem. 2000; 46: 1310–7
   PubMed Web of Science ®Google Scholar
• Loeb S, Chan DW, Sokoll L, Kan D, Maggiore J, Mikolajczyk SD, et al. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol. 2008; 180: 1959–62
   PubMed Web of Science ®Google Scholar
• Stephan C, Kahrs AM, Klotzek S, Reiche J, Müller C, Lein M, et al. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med. 2008; 46: 623–9
   PubMed Web of Science ®Google Scholar
• Jansen FH, Roobol M, Bangma CH, van Schaik RH. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem. 2008; 54: 1999–2006
   PubMed Web of Science ®Google Scholar
• Stephan C, Klaas M, Müller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006; 52: 59–64
   PubMed Web of Science ®Google Scholar
• Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006; 52: 1568–74
   PubMed Web of Science ®Google Scholar
• Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101: 374–83
   PubMedGoogle Scholar
• Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004; 59: 311–8
   PubMed Web of Science ®Google Scholar
• Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006; 3: CD004720
   Google Scholar
• Sandblom G, Varenhorst E, Löfman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004; 46: 717–23
   PubMed Web of Science ®Google Scholar
• Andriole, GL, Grubb, RL, 3rd, Buys, SS, Chia, D, TR Church, Fouad, MN, , et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–9.
   PubMed Web of Science ®Google Scholar
• de Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002; 98: 268–73
   PubMed Web of Science ®Google Scholar
• Zambon CF, Basso D, Prayer-Galetti T, Navaglia F, Fasolo M, Fogar P, et al. Quantitative PSA mRNA determination in blood: a biochemical tool for scoring localized prostate cancer. Clin Biochem. 2006; 39: 333–8
   PubMed Web of Science ®Google Scholar
• Gelmini S, Tricarico C, Petrone L, Forti G, Amorosi A, Dedola GL, et al. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin Chem Lab Med. 2003; 41: 261–5
   PubMed Web of Science ®Google Scholar
• Downes MR, Byrne JC, Pennington SR, Dunn MJ, Fitzpatrick JM, Watson RW. Urinary markers for prostate cancer. BJU Int. 2007; 99: 263–8
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457: 910–4
   PubMed Web of Science ®Google Scholar
• Shariat SF, Scardino PT, Lilja H. Screening for prostate cancer: an update. Can J Urol. 2008; 15: 4363–74
   PubMed Web of Science ®Google Scholar
• Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009; 27: 549–60
   PubMed Web of Science ®Google Scholar
• Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008; 54: 1951–60
   PubMed Web of Science ®Google Scholar
• Stavropoulou P, Gregorakis AK, Plebani M, Scorilas A. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta. 2005; 357: 190–5
   PubMed Web of Science ®Google Scholar
• Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and%free PSA. Prostate. 2003; 54: 220–9
   PubMed Web of Science ®Google Scholar
• Petricoin EF, 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002; 94: 1576–8
   PubMed Web of Science ®Google Scholar
• Abate-Shen C, Shen MM. Diagnostics: The prostate-cancer metabolome. Nature. 2009; 457: 799–800
   PubMed Web of Science ®Google Scholar
• Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res. 2009; 15: 1787–93
   PubMed Web of Science ®Google Scholar
• Litwin MS, Saigal CS, Lubeck DP, Li YP, Henning JM, Carroll PR. Health-related quality of life in men with metastatic prostate cancer: the misleading effect of lead-time bias. BJU Int. 2003; 91: 9–13
   PubMed Web of Science ®Google Scholar
• Saigal CS, Litwin MS. The economic costs of early stage prostate cancer. Pharmacoeconomics. 2002; 20: 869–78
   PubMed Web of Science ®Google Scholar